Solid Biosciences Inc. (SLDB)

Solid Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Net Income	-96.02	-85.98	-72.19	-88.29	-117.22
Depreciation & Amortization	2.58	2.41	2.96	3.92	2.82
Share-Based Compensation	7.63	7.54	13.37	11.63	14.21
Other Operating Activities	-8.37	-21.94	-21.91	16.14	7.48
Operating Cash Flow	-94.18	-97.98	-77.76	-56.6	-92.71
Capital Expenditures	-1.52	-2.42	-1.28	-0.9	-4.39
Acquisitions	0	31.52	0	0	0
Change in Investments	11.2	30.05	-89.81	7.5	28.9
Investing Cash Flow	9.69	59.16	-91.09	6.6	24.52
Share Issuance / Repurchase	3.12	72.73	134.99	132.49	49.33
Debt Issued / Paid	0	2.08	0	0	0
Other Financing Activities	-	0.02	-	-3.79	8.55
Financing Cash Flow	3.12	74.83	134.99	128.7	57.88
Net Cash Flow	-81.37	36.01	-33.87	78.7	-10.32
Free Cash Flow	-95.7	-100.39	-79.05	-57.5	-97.1
Free Cash Flow Margin	-	-1240.33%	-580.36%	-	-
Free Cash Flow Per Share	-4.81	-11.79	-11.11	-16.61	-36.15

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).